Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Peptide Therapy SummitPeptide Therapy Summit
Not Confirmed
Not Confirmed
03-05 April, 2025
Not Confirmed
Not Confirmed
05-09 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Peptide Therapy SummitPeptide Therapy Summit
Industry Trade Show
Not Confirmed
03-05 April, 2025
Industry Trade Show
Not Confirmed
05-09 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
27 Sep 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/09/27/2750240/0/en/Forcefield-Therapeutics-appoints-John-Tsai-MD-as-Chief-Executive-Officer.html
04 Apr 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/04/04/2640455/0/en/Forcefield-Therapeutics-signs-exclusive-patent-and-know-how-license-agreement-with-Freeline-Therapeutics.html
07 Nov 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/11/07/2549467/0/en/Forcefield-Therapeutics-presents-positive-preclinical-data-at-the-2022-Scientific-Sessions-of-American-Heart-Association.html
Details:
Under the terms of the agreement, Freeline gains rights to develop and commercialise AAV-based gene therapies for certain cardiac conditions using key targets identified by Forcefield.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: Spur Therapeutics
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Agreement April 04, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Spur Therapeutics
Deal Size : $0.6 million
Deal Type : Agreement
Details : Under the terms of the agreement, Freeline gains rights to develop and commercialise AAV-based gene therapies for certain cardiac conditions using key targets identified by Forcefield.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 04, 2023
Details:
Positive preclinical data of Chrdl1 in Science Translational Medicine, published today, outlines the mechanisms of the three proteins, which have been shown to restore heart function following a heart attack in mice.
Lead Product(s): Chrdl1
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 31, 2022
Lead Product(s) : Chrdl1
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Positive preclinical data of Chrdl1 in Science Translational Medicine, published today, outlines the mechanisms of the three proteins, which have been shown to restore heart function following a heart attack in mice.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 31, 2022
ABOUT THIS PAGE